SLQT stock forecast, quote, news & analysis
SelectQuote Inc is a technology-enabled, direct-to-consumer (DTC) distribution and engagement platform for selling insurance policies and healthcare services... Show more
SelectQuote (SLQT) Stock Analysis: Pharmacy Growth and Cash-Flow Discipline at a Sub-$1 Valuation
Key Takeaways
- SelectQuote operates a technology-enabled, direct-to-consumer platform that distributes senior (Medicare) insurance, life insurance, and healthcare services, including its SelectRx pharmacy.
- Over the trailing 30 days, SLQT shares have been roughly flat, trading near $0.41, after dipping into the low $0.30s in mid-October before recovering.
- Fiscal 2026 revenue rose 6% to $1.62 billion, while Healthcare Services became the company's largest revenue contributor at $845 million, up 14% year over year.
- Management is prioritizing cash generation and deleveraging, guiding to more than $60 million of operating cash flow for fiscal 2027.
- Medicare Advantage carrier discipline remains a key headwind, with approved policies expected to decline 10% to 15% in fiscal 2027.
- For deeper data, visit SelectQuote's Price Targets, Earnings, and Forecast pages to review analyst expectations and forward-looking metrics.
- Discover AI-driven trading strategies and automated market analysis by exploring Trending AI Robots.
Current Market Snapshot
SelectQuote, Inc. (NYSE: SLQT) has traded in a tight, low-priced range in recent weeks, with shares changing hands near $0.40 to $0.41. That leaves the stock firmly in sub-$1 territory, where small daily moves can still represent large percentage swings. Over the trailing 30 days, the shares have been essentially flat after a volatile stretch that saw them slide toward $0.30 in mid-October before stabilizing.
The broader market context reflects a company in transition: investors are weighing a durable, cash-generating Medicare distribution franchise against persistent Medicare Advantage headwinds, a sizable debt and preferred-equity burden, and open legal matters. A price-to-sales multiple well below 1 underscores the market's skepticism, even as management argues the shares materially discount the platform's cash-flow potential.
Business Overview and Competitive Position
Founded in 1985 and headquartered in Overland Park, Kansas, SelectQuote is a technology-enabled, direct-to-consumer distribution and engagement platform for insurance policies and healthcare services. It operates through three reportable segments: Senior, Healthcare Services, and Life, while de-emphasizing its legacy Auto & Home business.
The Senior segment sells Medicare Advantage, Medicare Supplement, Medicare Part D, and ancillary senior health products, supported by a large licensed agent workforce and proprietary data-driven lead routing. Healthcare Services encompasses the SelectRx patient-centered pharmacy, the Healthcare Select risk-assessment offering, and SelectPatient Management, a chronic-condition navigation platform. The Life segment distributes term life and final-expense products.
SelectQuote's competitive strength lies in its agent-led, technology-enabled distribution model and deep carrier relationships, which have produced consistent mid-20% adjusted EBITDA margins in the Senior business. Healthcare Services has become the company's largest revenue contributor, positioning pharmacy and population-health offerings as a key growth engine.
Recent Developments Driving SLQT
SelectQuote reported fourth-quarter and full-year fiscal 2026 results in late August 2026. Full-year revenue rose 6% to $1.62 billion, and adjusted EBITDA reached $109 million, above the company's prior $90 million to $100 million outlook. Operating cash flow improved by $44 million year over year to roughly $32 million.
Healthcare Services, including SelectRx, generated $845 million in fiscal 2026 revenue, up 14%, despite the effects of the Inflation Reduction Act and an earlier pharmacy benefit manager reimbursement renegotiation. The Senior segment produced $576 million in revenue, down 4%, while maintaining a 26% adjusted EBITDA margin amid ongoing Medicare Advantage carrier discipline.
Management has framed fiscal 2027 as an inflection point, guiding to $1.35 billion to $1.45 billion in revenue and $90 million to $115 million in adjusted EBITDA, with operating cash flow exceeding $60 million and free cash flow near $50 million. The company also identified more than $30 million of annualized expense savings tied to AI-enabled tools, process improvements, and organizational efficiency.
At the same time, investors continue to monitor a challenging capital structure — including a $350 million non-convertible preferred issuance completed in 2025 with a 14.5% dividend rate — as well as a U.S. Department of Justice qui tam action and a securities class action matter, which the company is defending.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of the platform's artificial intelligence-driven trading bots. While Tickeron offers hundreds of AI bots that trade thousands of tickers, only the top-performing and most relevant strategies are surfaced in this section, helping users filter out the noise. These bots vary considerably in approach, holding timeframe, and performance metrics, so investors can review each one's methodology and track record before drawing conclusions. For those seeking an automated, data-driven perspective on market conditions and individual securities, the Trending AI Robots section offers a practical starting point to explore what quantitative, AI-based analysis can contribute to the decision-making process.
2026 Outlook and What Investors Should Watch
Looking ahead, the key variables for SLQT are execution and cash generation rather than top-line growth. Management's fiscal 2027 guidance implies lower reported revenue, driven in part by the Inflation Reduction Act's effect on pharmacy revenue, alongside materially higher operating cash flow. Investors will be watching whether SelectQuote delivers on its $60 million-plus operating cash flow target and continues to expand Healthcare Services margins.
Medicare Advantage carrier behavior remains central to the Senior segment. With approved policies expected to decline 10% to 15% in fiscal 2027, the annual enrollment period and any shift in carrier marketing budgets will shape near-term results. Deleveraging and potential refinancing are also critical, given an approximate 12% blended cost of debt and preferred equity. Finally, the outcomes of the pending DOJ action and securities litigation, along with any change in analyst expectations, could meaningfully influence sentiment. These factors are forward-looking and subject to change, and they are not intended as investment advice.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for SLQT turns positive, indicating new upward trend
SLQT saw its Momentum Indicator move above the 0 level on October 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned positive. In 76 of the 92 cases, the stock moved higher in the following days. The odds of a move higher are at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
SLQT moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +22.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLQT advanced for three days, in 204 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The 10-day RSI Indicator for SLQT moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 26 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 53 cases where SLQT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLQT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
SLQT broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SLQT entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.241) is normal, around the industry mean (2.681). P/E Ratio (-8.002) is within average values for comparable stocks, (19.012). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (8.322). Dividend Yield (0.000) settles around the average of (0.039) among similar stocks. P/S Ratio (0.058) is also within normal values, averaging (2.968).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. SLQT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLQT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a technology-enabled, direct-to-consumer distribution platform that provides consumers with a transparent and convenient venue to shop for complex senior health, life and auto & home insurance policies from a curated panel of insurance carriers
Industry InsuranceBrokersServices